Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...

Moderna (MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

An AI collaboration boosted the company behind the largest U.S. cloud service on Monday, Nov. 3, 2025, while shares of the ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...

Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...

Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple ...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their ...